 Risha Gidwani
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 9 | 2022 | 665 | 3.650 |
Why?
| | Neoplasms | 10 | 2023 | 2105 | 1.780 |
Why?
| | Quality of Health Care | 4 | 2020 | 573 | 1.400 |
Why?
| | Hospice Care | 4 | 2019 | 185 | 1.240 |
Why?
| | Terminal Care | 4 | 2020 | 213 | 1.190 |
Why?
| | Lumbar Vertebrae | 4 | 2016 | 209 | 1.140 |
Why?
| | Veterans | 8 | 2020 | 1240 | 1.140 |
Why?
| | Oncologists | 2 | 2018 | 31 | 1.130 |
Why?
| | Ambulatory Care | 2 | 2020 | 479 | 1.100 |
Why?
| | United States Department of Veterans Affairs | 7 | 2020 | 556 | 1.080 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 151 | 0.990 |
Why?
| | Hospitals, Veterans | 5 | 2020 | 244 | 0.970 |
Why?
| | United States | 22 | 2023 | 12176 | 0.960 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2015 | 88 | 0.940 |
Why?
| | Health Care Reform | 2 | 2015 | 92 | 0.920 |
Why?
| | Financial Management | 1 | 2023 | 15 | 0.900 |
Why?
| | Venous Thrombosis | 2 | 2015 | 140 | 0.880 |
Why?
| | Pulmonary Embolism | 2 | 2015 | 181 | 0.850 |
Why?
| | Risk Adjustment | 2 | 2020 | 75 | 0.840 |
Why?
| | Medical Overuse | 3 | 2016 | 31 | 0.770 |
Why?
| | Hospitalization | 4 | 2020 | 1752 | 0.770 |
Why?
| | Aged | 19 | 2022 | 19079 | 0.740 |
Why?
| | Veterans Health | 2 | 2020 | 165 | 0.740 |
Why?
| | Breast Neoplasms | 2 | 2021 | 1868 | 0.700 |
Why?
| | Eligibility Determination | 1 | 2020 | 60 | 0.690 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 195 | 0.690 |
Why?
| | Comorbidity | 2 | 2021 | 1449 | 0.650 |
Why?
| | Fee-for-Service Plans | 1 | 2019 | 83 | 0.650 |
Why?
| | Public Health | 1 | 2023 | 434 | 0.640 |
Why?
| | Cancer Survivors | 1 | 2022 | 206 | 0.620 |
Why?
| | Patient Admission | 1 | 2020 | 176 | 0.620 |
Why?
| | Length of Stay | 2 | 2019 | 949 | 0.600 |
Why?
| | Medicare Part C | 1 | 2018 | 25 | 0.600 |
Why?
| | Low Back Pain | 2 | 2016 | 95 | 0.590 |
Why?
| | Retrospective Studies | 13 | 2023 | 12513 | 0.590 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 228 | 0.580 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 934 | 0.560 |
Why?
| | Palliative Care | 4 | 2017 | 641 | 0.560 |
Why?
| | Decision Making | 2 | 2020 | 781 | 0.550 |
Why?
| | Vaccines | 1 | 2022 | 375 | 0.550 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 126 | 0.540 |
Why?
| | Patient Care Management | 1 | 2016 | 53 | 0.540 |
Why?
| | Menorrhagia | 2 | 2013 | 14 | 0.540 |
Why?
| | Humans | 37 | 2023 | 114716 | 0.540 |
Why?
| | Intrauterine Devices, Medicated | 2 | 2013 | 23 | 0.530 |
Why?
| | Female | 25 | 2023 | 59486 | 0.520 |
Why?
| | Intensive Care Units | 2 | 2019 | 618 | 0.520 |
Why?
| | Job Satisfaction | 1 | 2017 | 168 | 0.520 |
Why?
| | Physicians, Family | 1 | 2017 | 201 | 0.520 |
Why?
| | Documentation | 1 | 2017 | 167 | 0.510 |
Why?
| | Consumer Health Information | 1 | 2015 | 47 | 0.480 |
Why?
| | Telemedicine | 1 | 2023 | 663 | 0.470 |
Why?
| | Proline | 1 | 2014 | 72 | 0.470 |
Why?
| | Chronic Disease | 2 | 2022 | 1590 | 0.460 |
Why?
| | Emergency Service, Hospital | 3 | 2015 | 1812 | 0.450 |
Why?
| | Endometrial Ablation Techniques | 1 | 2013 | 2 | 0.440 |
Why?
| | Attitude of Health Personnel | 3 | 2018 | 977 | 0.440 |
Why?
| | Patient Satisfaction | 1 | 2017 | 583 | 0.440 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2014 | 132 | 0.440 |
Why?
| | Family Practice | 1 | 2017 | 427 | 0.440 |
Why?
| | Antiviral Agents | 2 | 2019 | 646 | 0.440 |
Why?
| | Menstruation | 1 | 2013 | 35 | 0.440 |
Why?
| | Oligopeptides | 1 | 2014 | 234 | 0.430 |
Why?
| | Male | 20 | 2020 | 55558 | 0.420 |
Why?
| | Middle Aged | 15 | 2021 | 26746 | 0.420 |
Why?
| | Cost-Benefit Analysis | 4 | 2020 | 545 | 0.390 |
Why?
| | Spinal Fusion | 1 | 2014 | 200 | 0.380 |
Why?
| | AIDS Serodiagnosis | 1 | 2011 | 29 | 0.370 |
Why?
| | Internet | 1 | 2015 | 595 | 0.370 |
Why?
| | Azacitidine | 1 | 2011 | 129 | 0.360 |
Why?
| | Health Status | 1 | 2015 | 723 | 0.350 |
Why?
| | Myelodysplastic Syndromes | 1 | 2011 | 119 | 0.350 |
Why?
| | Disease Progression | 1 | 2015 | 2384 | 0.310 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 751 | 0.310 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3031 | 0.300 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1176 | 0.300 |
Why?
| | Hospices | 3 | 2018 | 83 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1178 | 0.290 |
Why?
| | Administrative Claims, Healthcare | 2 | 2018 | 21 | 0.280 |
Why?
| | Mass Screening | 2 | 2011 | 1003 | 0.280 |
Why?
| | Primary Health Care | 1 | 2016 | 1515 | 0.280 |
Why?
| | Patient Acceptance of Health Care | 2 | 2022 | 679 | 0.250 |
Why?
| | Hepacivirus | 2 | 2019 | 229 | 0.250 |
Why?
| | Interviews as Topic | 2 | 2018 | 582 | 0.240 |
Why?
| | Logistic Models | 2 | 2023 | 1843 | 0.240 |
Why?
| | Pandemics | 2 | 2023 | 1319 | 0.230 |
Why?
| | Hospitals, Private | 1 | 2023 | 11 | 0.230 |
Why?
| | California | 2 | 2023 | 356 | 0.220 |
Why?
| | Levonorgestrel | 2 | 2013 | 31 | 0.210 |
Why?
| | Qualitative Research | 2 | 2018 | 935 | 0.210 |
Why?
| | Aged, 80 and over | 5 | 2020 | 6346 | 0.200 |
Why?
| | Medically Uninsured | 1 | 2022 | 122 | 0.190 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2022 | 99 | 0.190 |
Why?
| | Insurance Coverage | 1 | 2022 | 201 | 0.180 |
Why?
| | Privatization | 1 | 2020 | 7 | 0.180 |
Why?
| | Insurance, Health | 1 | 2022 | 244 | 0.180 |
Why?
| | Adult | 8 | 2018 | 30543 | 0.170 |
Why?
| | HIV Infections | 2 | 2011 | 2469 | 0.170 |
Why?
| | Probability | 1 | 2020 | 291 | 0.170 |
Why?
| | Databases, Factual | 2 | 2014 | 1126 | 0.170 |
Why?
| | Financing, Personal | 1 | 2019 | 25 | 0.170 |
Why?
| | Publishing | 1 | 2020 | 125 | 0.160 |
Why?
| | Needs Assessment | 1 | 2020 | 313 | 0.160 |
Why?
| | Medicaid | 1 | 2023 | 407 | 0.160 |
Why?
| | Hospitals | 1 | 2023 | 580 | 0.160 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1080 | 0.160 |
Why?
| | Health Expenditures | 1 | 2019 | 171 | 0.150 |
Why?
| | Cost of Illness | 1 | 2019 | 254 | 0.140 |
Why?
| | Bereavement | 1 | 2017 | 49 | 0.140 |
Why?
| | Alcohol Deterrents | 1 | 2016 | 17 | 0.140 |
Why?
| | Utilization Review | 1 | 2016 | 34 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 268 | 0.130 |
Why?
| | Drug Therapy | 1 | 2015 | 77 | 0.130 |
Why?
| | Alcohol-Related Disorders | 1 | 2016 | 113 | 0.120 |
Why?
| | Publications | 1 | 2015 | 37 | 0.120 |
Why?
| | Cohort Studies | 2 | 2023 | 4899 | 0.120 |
Why?
| | Radiotherapy | 1 | 2015 | 176 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2014 | 69 | 0.120 |
Why?
| | Interprofessional Relations | 1 | 2016 | 249 | 0.120 |
Why?
| | Cell Phone | 1 | 2015 | 76 | 0.120 |
Why?
| | Medical Informatics | 1 | 2015 | 92 | 0.120 |
Why?
| | Policy Making | 1 | 2014 | 81 | 0.120 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 473 | 0.120 |
Why?
| | Confidence Intervals | 1 | 2014 | 309 | 0.110 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 68 | 0.110 |
Why?
| | Ribavirin | 1 | 2014 | 89 | 0.110 |
Why?
| | Parents | 1 | 2022 | 1190 | 0.110 |
Why?
| | Interferons | 1 | 2014 | 151 | 0.110 |
Why?
| | Drug Utilization | 1 | 2014 | 167 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 462 | 0.110 |
Why?
| | Danazol | 1 | 2013 | 2 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2022 | 1183 | 0.110 |
Why?
| | Treatment Outcome | 2 | 2020 | 9089 | 0.110 |
Why?
| | Interferon-alpha | 1 | 2014 | 187 | 0.110 |
Why?
| | Respiration, Artificial | 1 | 2017 | 526 | 0.110 |
Why?
| | Quality Improvement | 1 | 2020 | 951 | 0.110 |
Why?
| | Family | 1 | 2017 | 590 | 0.110 |
Why?
| | Odds Ratio | 1 | 2016 | 954 | 0.110 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2014 | 109 | 0.110 |
Why?
| | Interleukins | 1 | 2014 | 236 | 0.110 |
Why?
| | Progestins | 1 | 2013 | 75 | 0.100 |
Why?
| | Patient Compliance | 1 | 2016 | 525 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4406 | 0.100 |
Why?
| | Reoperation | 1 | 2014 | 514 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 954 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 4622 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2013 | 331 | 0.100 |
Why?
| | Communication | 1 | 2016 | 747 | 0.090 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 246 | 0.090 |
Why?
| | Quality of Life | 2 | 2018 | 2357 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2016 | 801 | 0.080 |
Why?
| | Community-Based Participatory Research | 1 | 2010 | 130 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 973 | 0.080 |
Why?
| | Incidence | 1 | 2014 | 2312 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1214 | 0.080 |
Why?
| | Health Care Costs | 1 | 2011 | 380 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2199 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2014 | 3004 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1895 | 0.070 |
Why?
| | Risk Assessment | 1 | 2014 | 2973 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2010 | 763 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2014 | 2127 | 0.060 |
Why?
| | Brazil | 1 | 2022 | 90 | 0.050 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 328 | 0.040 |
Why?
| | Disulfiram | 1 | 2016 | 13 | 0.030 |
Why?
| | Consumer Behavior | 1 | 2017 | 65 | 0.030 |
Why?
| | Taurine | 1 | 2016 | 41 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 100 | 0.030 |
Why?
| | Nursing Homes | 1 | 2017 | 136 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 83 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 10462 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 137 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 221 | 0.030 |
Why?
| | Pregnancy, Unplanned | 1 | 2013 | 33 | 0.030 |
Why?
| | Models, Economic | 1 | 2013 | 48 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2013 | 101 | 0.030 |
Why?
| | Hysterectomy | 1 | 2013 | 106 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1690 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2015 | 507 | 0.020 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 436 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2010 | 127 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2762 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 232 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 925 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 822 | 0.020 |
Why?
| | Pregnancy | 1 | 2013 | 5525 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 17808 | 0.010 |
Why?
|
|
Gidwani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|